Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MRNABullishMarket Recapnews

High materiality7/10

Moderna shows bullish one-month setup on key technical signal

Aug 6, 2026, 2:42 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A historically reliable one-month signal suggests upside; concurrent catalyst (flu vaccine approval) adds optionality; short interest dynamics imply potential short-squeeze upside if sentiment shifts and options unwind.

AI summary

What happened, with direct paths to the underlying reporting

Moderna trades around $55 after FDA-approved flu vaccine; a historical 100-day/20-day ATR signal suggests near-term upside with an 82% one-month win rate historically. Short interest remains elevated though down 11% recently, and options positioning leans bearish, implying potential unwinding could spark a rally if sentiment shifts.

MRNA near a bullish 100-day/20-day ATR signal; 82% one-month gain historically.
Short interest: 52.40M shares, 14.3% float; ~7 days to cover.
FDA-approved flu vaccine cited as a near-term catalyst for MRNA.
Options positioning bearish; SOIR 1.055 near annual high; potential unwind.
Broker sentiment mixed: 22/24 hold or worse; 12-month target $55.12.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Moderna shows bullish one-month setup on key technical signal

Moderna's melanoma vaccine advances; market potential by 2027 with Merck collaboration

Moderna Announces Major Private Debt Offering, Shares Fall on Term Disclosure

FDA Approves Moderna 2026-27 COVID Vaccines, Boosting Near-Term Prospects

Moderna Gains Bullish Momentum Signal From Power Inflow Alert